A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.
Also called NCT04596631
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 132 participants
- Sponsor
- Registry
-
NCT04596631 -
2018-002952-34
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Czechia, Greece, India, Israel, Lebanon, Malaysia, Mexico, Morocco, Netherlands, New Zealand, North Macedonia, Portugal, Puerto Rico, Romania, Russia, Taiwan, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04596631. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-02 (actual); primary completion 2025-04-29 (actual). Results posted on 2026-08-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
- Acronym
- PIONEER TEENS
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Oral semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04596631- Content hash
23035404ff77489e886fbd1186dcbe2892f2b65177fc76ad007bba8790310522